Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has demonstrated a solid financial trajectory, with fourth quarter gross margin expected to reach 73% to 75%, contributing to a full-year gross margin improvement to approximately 72%, indicative of operational efficiency. The company achieved $9.5 million in revenue for the quarter, reflecting a 10% year-over-year growth, driven by enhanced distributor-driven sales and improving geographic market execution. Additionally, recent clinical publications and the advancement of DrugSorb-ATR toward FDA submission bolster the firm's strategic position and potential for future growth across various critical care applications.

Bears say

CytoSorbents Corp reported fourth-quarter revenue of approximately $9.2 million, remaining flat year-over-year, while the full-year revenue reached about $37 million, showing only 4% growth compared to the previous year. Management has noted patient imbalances in the initial U.S. market, which could signal underlying challenges in demand and market acceptance of their products. The company's current valuation appears to be distressed, reflecting market concerns that are largely independent of the company's fundamental performance metrics.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.